IM Cannabis vs MediWound
IMCC and MDWD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IMCC and MDWD compare
IM Cannabis grew revenue faster over the last twelve months (1.3% versus −16.1% for MediWound).
IM Cannabis scores higher on the StockData Score (4 against 2 for MediWound), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IMCC | MDWD |
|---|---|---|
| Size and price | ||
| Share price | $0.568 | $12.97 |
| Change, 1 year | −98.7% | −30.0% |
| Change, 5 years | −100.0% | −35.4% |
| Beta (5Y) | 1.35 | 0.90 |
| Employees | 95 | 35 |
| StockData Score | ||
| Total score | 4 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 1.3% (better) | −16.1% |
| Revenue growth, 5Y average | 28.1% (better) | −4.9% |
| Profitability | ||
| Gross margin | 17.7% | 19.2% (better) |
| Operating margin | −21.2% (better) | −149% |
| Net margin | −20.7% | – |
| FCF margin | 8.6% (better) | −128% |
| Return on invested capital | −82.3% | – |
| Financial health | ||
| Interest coverage | −3.3× (better) | −10.3× |
| Current ratio | 0.56 | 2.32 (better) |
| Piotroski F-score | 4 | – |
| Ownership | ||
| Held by institutions | – | 45.3% |
| Held by insiders | 0.00% | 23.4% |
| Insider net buying, 12 months | – | $60.6K |
| Short interest, % of float | – | 18.2% |
Go deeper
- IMCC stock overview
- IMCC income statement
- IMCC valuation and score
- MDWD stock overview
- MDWD income statement
- MDWD valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.